Business

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

Financial Post · October 19, 2026 at 7:41 a.m.

CAMBRIDGE, Mass., Oct.

19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI ® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, including investigational felzartamab, at the American Society of Nephrology (ASN) Kidney Week taking place from October 22 to 25, 2026 in Denver, Colorado.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

More from Financial Post

Transaction in Own Shares

Purecore Closes $3.52M Oversubscribed Non-Brokered Private Placement

Videa and ClearDent Partner to Bring Embedded AI Imaging to Canadian Dental Practices

Samsung Canada Opens Applications for Galaxy Campus Crew, a New National Program for Post-Secondary Students

More in Business

Transaction in Own Shares

Purecore Closes $3.52M Oversubscribed Non-Brokered Private Placement

Videa and ClearDent Partner to Bring Embedded AI Imaging to Canadian Dental Practices

Samsung Canada Opens Applications for Galaxy Campus Crew, a New National Program for Post-Secondary Students

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings

Inflation risks are rising as oil shock lingers, Macklem says